Concepedia
Statistics
Publications
10
Citations
429
H-Index
Active since
1997
Affiliations
Goethe University Frankfurt(Current)
The Alfred Hospital
Dana-Farber Cancer Institute
Peter MacCallum Cancer Centre
Novartis (United States)
Kathryn Parker is an author at Goethe University Frankfurt specializing in medicine, pharmacology, and oncology.
Publications per year
1997–2014
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla et al. · Leukemia · 2013 · 138 citations
Medicine, Oncology, Pharmacology +17
Comparison of subjective sleep quality in patients with cancer and healthy subjects.
D C Owen, Kathryn Parker, Deborah B. McGuire · PubMed · 1999 · 70 citations
Nursing, Oncology, Health Assessment +16
Bdnf Deletion or TrkB Impairment in Amygdala Inhibits Both Appetitive and Aversive Learning
Scott A. Heldt, Kelsey S. Zimmermann, Kathryn Parker et al. · Journal of Neuroscience · 2014 · 50 citations · Full text
Medicine, Neurobiology, Neuroscience +17
Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.
Oliver G. Ottmann, Andrew Spencer, H. Miles Prince et al. · Blood · 2008 · 50 citations
Medicine, Oncology, Pharmacology +13
Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Kathryn Parker, William E. Mitch, John C. Stivelman et al. · Journal of the American Society of Nephrology · 1997 · 41 citations · Full text
Medicine, Hematology, Pharmacotherapy +16
1–5 of 10